Get the Stockscreener App
207.94
2.10%
-4.46
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $207.94, with a volume of 4.61M.
It is down -2.10% in the last 24 hours and down -8.40% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$212.40
Open:
$213.55
24h Volume:
4.61M
Relative Volume:
0.64
Market Cap:
$367.80B
Revenue:
$61.16B
Net Income/Loss:
$4.19B
P/E Ratio:
88.06
EPS:
2.3614
Net Cash Flow:
$17.82B
1W Performance:
-0.43%
1M Performance:
-8.40%
6M Performance:
-9.79%
1Y Performance:
+19.37%
1-Day Range:
$207.75
$214.10
1-Week Range:
$201.66
$214.10
52-Week Range:
$168.54
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
207.94 | 367.80B | 61.16B | 4.19B | 17.82B | 2.3614 |
LLY
Lilly Eli Co
|
939.47 | 839.28B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
238.46 | 574.36B | 94.19B | 26.80B | 19.70B | 11.05 |
AZN
Astrazeneca Plc
|
204.03 | 316.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
121.42 | 299.89B | 64.93B | 18.26B | 12.36B | 7.2751 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Haisco Pharmaceutical Signs Licensing Agreement With AbbVie Group - TradingView — Track All Markets
AbbVie stock price forecast: sellers in control as ABBV fails to hold above support - Traders Union
Massachusetts Financial Firm Trims Stake in AbbVie - National Today
-2.05% for AbbVie stock as renewed selling keeps shares below key resistance - Traders Union
Factory Mutual Insurance Co. Decreases AbbVie Stock Position - National Today
AbbVie (ABBV) Receives a Buy from RBC Capital - The Globe and Mail
CapEx per share of AbbVie, Inc. – BSESOF:4AB - TradingView — Track All Markets
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
Sector Update: Health Care - Moomoo
3 Companies Aggressively Raising Dividends While Others Play Defense - Investing.com
RBC Capital reiterates Abbvie stock Outperform rating at $260 target - Investing.com
Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer? - Yahoo Finance
Night Vision Disturbances Pipeline 2026: MOA, ROA, - openPR.com
AbbVie First-Quarter Earnings Unlikely to Lift Sentiment, RBC Says - Moomoo
Guggenheim Adjusts Price Target on AbbVie to $249 From $242, Maintains Buy Rating - marketscreener.com
Dividend Roundup: AGNC Investments, Abbott Labs, AbbVie, and more (AGNC:NASDAQ) - Seeking Alpha
Guggenheim raises Abbvie stock price target to $249 on immunology By Investing.com - Investing.com Canada
Daner Wealth Management, LLC's AbbVie Inc(ABBV) Holding History - GuruFocus
BNY Mellon Worldwide Growth Fund, Inc.'s AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie Sues Over 340B Patient Definition In Chicago Area - Hoodline
AbbVie: Fairly Valued And Positioned For Growth (NYSE:ABBV) - Seeking Alpha
Cantor Fitzgerald Lowers AbbVie (ABBV) Target, Sees Weak Pharma Catalyst Ahead - Yahoo Finance
ABBV Stock Quote Price and Forecast - CNN
Is AbbVie (ABBV) Still Attractive After Recent Pullback And Mixed Valuation Signals - simplywall.st
TrumpRx adds more drugs as AbbVie, Genentech join self-pay platform - TechTarget
AbbVie: Buy Or Sell Ahead Of Q1 Earnings? It's A Buy, But With Caveats (Upgrade) (ABBV) - Seeking Alpha
AbbVie wades into drug discount fight, suing feds over provider audits - Crain's Chicago Business
AbbVie challenges 340B patient definition in US court - The Pharma Letter
Exclusive: AbbVie sues to narrow drug discount patient definition - Axios
Lobbying Update: $80,000 of ABBVIE INC. lobbying was just disclosed - Quiver Quantitative
AbbVie Dividend Growth & Portfolio Outlook 2026News and Statistics - IndexBox
AbbVie Says 340B Program Defines 'Patient' Too Broadly - Law360
AbbVie files lawsuit to address 'outdated' drug discount eligibility program - Reuters
AbbVie Sue US Over ‘Patient’ Definition Under Drug Discount Plan - Bloomberg Law News
Buying pressure lifts AbbVie stock higher in today's trading - Traders Union
AbbVie sues to narrow 340B eligibility - FirstWord Pharma
AbbVie (ABBV) Challenges Government's Drug Discount Program Defi - GuruFocus
AbbVie : moves to close loopholes and strengthen accountability in 340B program - marketscreener.com
Abbvie Files Lawsuit To Address 340B Program Guidance - TradingView
AbbVie: Upside Potential And Dividends With Competent Portfolio Renewal (NYSE:ABBV) - Seeking Alpha
ABBV: Cantor Fitzgerald Lowers Price Target, Maintains Overweigh - GuruFocus
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Cantor Fitzgerald lowers Abbvie stock price target on valuation - Investing.com
BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year - AbbVie News Center
$20,000 grants return as BOTOX reopens program for 250 women - Stock Titan
AbbVie Stock Review 2026: Earnings Outlook, Dividend Yield, and ValuationNews and Statistics - IndexBox
Ethos Capital Buys Stake in AbbVie - National Today
Can AbbVie’s (ABBV) New Dermatology Data Quietly Reshape Its Immunology-Heavy Investment Story? - Yahoo Finance
AbbVie: Lowered Guidance Is Just NoiseReiterate Buy - Seeking Alpha
AbbVie Continues to Raise Quarterly Dividend Amid Patent Challenges - Intellectia AI
This Pharma Dividend Has Been Raised Every Single Year for Over a Decade - Yahoo Finance
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):